AKT1 and fragile X syndrome: By using the FDA-approved trifluoperazine, we demonstrate that acute administration of a drug with PI3K inhibiting activity is sufficient to rescue multiple aspects of FXS-associated pathology, supporting the practical value of targeting PI3K-Akt-S6K1 signaling.